Skip to main content
49°
Mostly Cloudy
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis AG Common Stock
(NY:
NVS
)
109.03
+0.39 (+0.36%)
Streaming Delayed Price
Updated: 3:55 PM EDT, Mar 13, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novartis AG Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
These 2 Vanguard ETFs Are Crushing the S&P 500 in 2025. Should You Buy?
March 11, 2025
Via
The Motley Fool
Topics
ETFs
Stocks
Exposures
US Equities
Teladoc Health Partners With Eli Liily's LillyDirect to Expand Access to Zepbound For Weight Loss
March 06, 2025
Teladoc Health teams up with Eli Lilly's LillyDirect to improve Zepbound access, offering direct home delivery and comprehensive obesity care support.
Via
Benzinga
Novartis Earns Near-Best Overall Rating As Profit Growth Climbs
March 05, 2025
Novartis ranks No. 1 among in the 33-stock Medical-Ethical Drugs industry group. Novartis got a Composite Rating upgrade to 96 on Wednesday.
Via
Investor's Business Daily
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) stands out as a stock that provides good value for the fundamentals it showcases.
March 04, 2025
Uncover the potential of NOVARTIS AG-SPONSORED ADR, an undervalued stock. NYSE:NVS maintains a strong financial position and offers an appealing valuation.
Via
Chartmill
Novartis Earnings Surprised The Street; Still Going Strong Despite Market Correction
March 04, 2025
Highly ranked Novartis is forming the right side of a long cup base with a buy point of 120.92. And it's literally running higher.
Via
Investor's Business Daily
Is the Market Bullish or Bearish on Novartis?
February 26, 2025
Via
Benzinga
Uncovering Dividend Opportunities with NYSE:NVS.
January 27, 2025
Uncovering Dividend Opportunities with NOVARTIS AG-SPONSORED ADR (NYSE:NVS).
Via
Chartmill
Roche Touts Food Allergy Drug As Superior Than Oral Immunotherapy
March 03, 2025
Roche's Xolair outperformed oral immunotherapy in a Phase 3 trial for food allergies, showing better tolerance and fewer adverse events.
Via
Benzinga
3 Dividend Stocks That Are No-Brainer Buys Right Now
March 01, 2025
Via
The Motley Fool
Court Dismisses Novartis Challenge To Medicare Drug Price Negotiation Program
February 26, 2025
A federal court rejected Novartis' legal challenge to the Medicare Drug Price Negotiation Program, ruling that it does not impose unconstitutional fines, takings, or compelled speech.
Via
Benzinga
NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects
February 24, 2025
Multiple sclerosis patients report severe side effects, including relapses and mobility issues, after switching from Tysabri to Tyruko in an NHS cost-saving move. Regulators and experts are assessing...
Via
Benzinga
This Kraft Heinz Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday
February 13, 2025
Via
Benzinga
Novartis To Beef Up Heart Disease Offering With $3 Billion Blackstone-Backed Anthos Therapeutics Deal
February 11, 2025
Novartis is acquiring Anthos Therapeutics for up to $3.08 billion, adding abelacimab, a late-stage anticoagulant, to its cardiovascular portfolio.
Via
Benzinga
Super Bowl Commercials 2025: Complete List of Super Bowl LIX Ads And Companies Behind Them
February 10, 2025
The list of Super Bowl LIX commercials and the companies behind the Super Bowl ads.
Via
Benzinga
Super Bowl LIX Commercials: AI, Celebs, Muppets, Warren Buffett-Linked Brand Take The Spotlight
February 07, 2025
A list of Super Bowl LIX commercials and the celebrities and athletes attached to star in the ads.
Via
Benzinga
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
2 High-Yield Dividend Stocks to Hold Through 2025 and Beyond
February 03, 2025
Via
The Motley Fool
Novartis Ag (NVS) Q4 2024 Earnings Call Transcript
January 31, 2025
NVS earnings call for the period ending December 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Novartis Gets Retail Chatting After Upbeat Q4, But Sentiment Stays Tepid Amid Volatile Trading
January 31, 2025
The company is facing upcoming patent expirations for three key drugs, with Entresto expected to face generic competition in the U.S. mid-year.
Via
Stocktwits
Topics
Intellectual Property
Exposures
Intellectual Property
Novartis Edges Higher On Sales Beat As Competition Looms For Its Biggest Moneymaker
January 31, 2025
The company's biggest moneymaker is expected to face off with lower-cost generics this summer.
Via
Investor's Business Daily
Topics
Earnings
Exposures
Financial
US Stock Futures Climb After Apple Beats Q4 Expectations: Expert Says Tech Stocks Hold Above Key Level Despite DeepSeek Impact
January 31, 2025
US stock futures climbed on Friday, pointing to a third straight week of gains fueled by strong corporate earnings.
Via
Benzinga
Novartis Q4: Earnings Beat Estimates, CEO Dismisses Entresto Patent Expiration Worries
January 31, 2025
Novartis reported strong Q4 earnings and sales growth, with CEO Narasimhan reportedly downplaying concerns over Entresto's U.S. patent expiration while projecting continued growth in 2025.
Via
Benzinga
Topics
Earnings
Intellectual Property
Exposures
Financial
Intellectual Property
When you look at NYSE:NVS, it's hard to ignore the strong fundamentals, especially considering its likely undervaluation.
January 31, 2025
NOVARTIS AG-SPONSORED ADR is a hidden gem, featuring undervaluation and robust fundamentals. NYSE:NVS showcases decent financial health and profitability, coupled with an attractive price.
Via
Chartmill
Earnings Scheduled For January 31, 2025
January 31, 2025
Via
Benzinga
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
January 30, 2025
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.
Via
Benzinga
RFK Jr. And Big Pharma: Health Secretary Hopeful Answers Pointed Questions On Drugs, Insurance, Trump Exec Orders
January 29, 2025
Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.
Via
Benzinga
Topics
Government
Exposures
Political
AI Pharma: 2 Paths to AI-Powered Drug Investment
January 28, 2025
AI is transforming drug development, allowing companies to identify new drug targets, optimize clinical trials and speed delivery of medicines to patients.
Via
MarketBeat
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst
January 22, 2025
Cytokinetics receives a Buy rating from Stifel, with a promising outlook for aficamten in the $3 billion U.S. oHCM market, despite investor concerns over M&A and deals.
Via
Benzinga
Google Parent-Owned Startup To Launch AI-Designed Drug Trials By Year-End, Partnering With Eli Lilly And Novartis To Tackle Major Diseases
January 22, 2025
An Alphabet-backed startup is poised to begin clinical trials of its first artificial intelligence-designed drug by year-end.
Via
Benzinga
Outlook Therapeutics Vision Loss Drug At Par With Novartis Drug
January 16, 2025
Outlook Therapeutics plans to resubmit ONS-5010 for FDA approval in 2025 following NORSE EIGHT trial results in wet AMD patients.
Via
Benzinga
Exposures
Product Safety
Don't overlook NYSE:NVS—it's a hidden gem with strong fundamentals and an attractive price tag.
January 10, 2025
Investors should take notice ofNOVARTIS AG-SPONSORED ADR (NYSE:NVS)—it offers a great deal for the fundamentals it presents.
Via
Chartmill
< Previous
1
2
3
4
5
6
7
8
9
...
43
44
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.